CP and COVID-19: Examining the subset of subjects who had not yet received CP and under 70 years of age (i.e., capable of expressing ACE2 RNA in blood cells) resulted in a more extreme differential prevalence of ACE2 RNA expression: 77% of working volunteers versus 21% of those hospitalized with severe COVID-19.